Brief: Ab&B Bio Tech Co Ltd JS Announces Approval For Quadrivalent Subunit Influenza Vaccine By China's NMPA
03/09/2025 11:25
Sept 3 (Reuters) - Ab&B Bio Tech Co Ltd JS 2627.HK: APPROVAL OF APPLICATION FOR QUADRIVALENT SUBUNIT INFLUENZA VACCINE BY CHINA'S NMPA Further company coverage: 2627.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ab&B Bio Tech Co JS
See all newsBrief: Ab&B Bio Tech Enters Strategic Cooperation Agreement With Walvax Hong Kong
Ab&B Bio Tech hits record high on inclusion in Hang Seng Composite Index
Brief: AB&B Bio Tech Co Ltd JS Says H Shares Included In Hang Seng Composite Index Effective March 9
Ab&B gains as human rabies vaccine commences Phase III clinical trials
Brief: Ab&B Bio Tech Co Ltd JS Announces Approval For Quadrivalent Subunit Influenza Vaccine By China's NMPA